Abstract. Hepatocellular carcinoma (HCC) is one of the most common life-threatening malignancies in the world. The molecular mechanisms leading to the development of HCC are complex and only recently have they begun to be clarified. Integrin linked-kinase (ILK), a multifunctional signaling and scaffold protein of focal adhesion plaques, has been implicated in the pathogenesis of several human malignancies. In the current study the expression of ILK, ß-catenin and E-cadherin and the phosphorylation of Akt were studied by immunohistochemistry in 69 human HCCs and adjacent normal and cirrhotic liver parenchyma. ILK and phosphorylated-Akt (p-Akt) immunostaining was observed in 100 and 79.7% of HCCs, respectively, and their protein levels correlated significantly. Activation of ß-catenin and downregulation of E-cadherin were frequently observed in HCC, but they were not related to ILK expression. A strong correlation between ILK expression and phosporylation of Akt was also observed in cirrhotic liver. Moreover, downregulation of E-cadherin and membranous ß-catenin were found in cirrhotic tissue suggesting their involvement in the liver tissue remodeling observed in cirrhosis. Our results indicate that ILK overexpression during liver oncogenesis and cirrhosis correlates with activation of Akt but not with other conventional ILK targets.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancerrelated mortality (1) . Hepatocarcinogenesis is a multistage process involving different genetic alterations that ultimately lead to oncogenic transformation of the hepatocyte. Cirrhosis of any aetiology may be complicated by HCC and is the greatest single risk factor. Although the major risk factors of HCC are well defined, the molecular mechanisms that regulate its development remain largely unknown.
Integrin-linked kinase (ILK), a serine/threonine kinase located in focal adhesion plaques, interacts with ß integrins and numerous cytoskeleton-associated proteins (2, 3) and regulates signaling pathways involved in cell cycle progression, apoptosis, cell adhesion and tumor invasion (4) (5) (6) (7) . Overexpression of ILK in epithelial cell lines has been shown to result in nuclear accumulation of ß-catenin, activation of Akt and downregulation of E-cadherin (8) (9) (10) . Increased expression of ILK has also been reported in many human cancers such as prostate, colon, ovarian cancer and melanoma (11) (12) (13) (14) .
In vitro studies implicate ILK in the regulation of hepatocyte survival and differentiation (15) . ILK has also been found involved in liver wound healing and chemically-induced rat hepatocarcinogenesis (16, 17) . Recently, ILK was shown to be overexpressed in HCC (18) . However, ILK signaling pathways in HCC and liver cirrhosis have not been fully addressed. In a series of hepatocellular carcinomas, surrounding cirrhotic liver and adjacent normal liver tissue, we evaluated by immunohistochemistry the expression of ILK, ß-catenin, E-cadherin and the phosphorylation of Akt at Ser473. Potential correlations between these factors and their relationships to clinical and pathologic parameters of the disease such as tumor grade and presence of underlying cirrhosis were also examined.
Materials and methods
Tissue specimens. The study was performed in accordance with institutional ethical guidelines and was approved by the Committee on Research and Ethics and the Scientific Committee of the University Hospital of Patras, Greece. Formalin-fixed paraffin-embedded tissue specimens from 69 human HCCs were obtained from the Department of Pathology, 'Areteion' Hospital, Athens, Greece. Tumors were graded according to World Health Organization (WHO) criteria, and they included 22 well differentiated (grade I), 24 moderately differentiated (grade II) and 23 poorly differentiated (grade III) HCCs. In 47/69 HCC specimens, hepatitis B virus (HBV)-related cirrhosis was present in liver parenchyma adjacent to the tumor while in the rest of the cases there was no underlying cirrhosis as confirmed by clinical information and histological examination. (Fig. 1A) . All HCCs examined (100%) were positive for ILK. Staining was mainly observed in the cytoplasm of tumors cells (Fig. 1B) . Table I . Antibody characteristics. 
P, polyclonal rabbit; M, monoclonal mouse; TBS, Tris-buffered saline; BSA, bovine serum albumin.
- Table II . ILK expression in human hepatocellular carcinomas and correlation with clinicopathological parameters. 
a ILK expression was scored as described in Materials and methods.
b Kruskal-Wallis or Mann-Whitney test. A p-value <0.05 was considered statistically significant.
In 63/69 tumors (91.3%) ILK expression was moderate or strong and only 6/69 (8.7%) cases showed weak expression. In HCCs there was no statistically significant correlation of ILK expression with tumor grade or the presence of cirrhosis (Table II) . Positive ILK staining was also observed in 40/47 (85.1%) cases of cirrhotic liver (Fig. 1C) . ILK expression was weak in 20/47 (42.6%), moderate in 17/47 (36.2%) and strong in 3/47 (6.4%) cases of cirrhosis. ILK expression was significantly higher in cirrhosis compared to normal liver (p<0.001) and in HCCs compared to cirrhotic and normal liver (p<0.001).
Activation of Akt is frequently observed in HCCs and cirrhosis and correlates significantly with ILK expression.
Phosphorylation of Akt was examined in 69 tumors and adjacent cirrhotic and normal liver tissue. In normal liver, p-Akt immunostaining was absent (Fig. 1D ). In contrast, phosphorylation of Akt was observed in 55/69 HCCs (79.7%) (Fig. 1E) . Immunostaining of p-Akt was mainly found in the cytoplasm of cancer cells and only in 17/69 (24.6%) cases was a nuclear localization also noted. There was no correlation of p-Akt with tumor grade. However, phosphorylation of Akt in HCCs was significantly higher in cases without underlying liver cirrhosis (p=0.017) compared to the tumors occurring in the setting of cirrhosis (Table III) . Thirty-five of 47 (74.3%) cases of cirrhotic liver were positive for p-Akt cytoplasmic staining (Fig. 1F) . In 28/47 (59.6%) cases of cirrhosis, p-Akt staining was weak, while 7/47 (14.9%) cases showed moderate staining. In cirrhosis, nuclear p-Akt localization was also observed in 34/47 cases (74.5%). Cytoplasmic and nuclear levels of p-Akt were significantly higher in carcinomas compared with cirrhosis (p=0.003 and p<0.001, respectively). Notably, phosphorylation of Akt correlated significantly with overexpression of ILK in HCC (r=0.420, p=0.002) as well as in cirrhosis (r=0.511, p<0.001) (Figs. 2 and 3) .
Activation of ß-catenin during liver oncogenesis does not correlate with ILK expression.
The subcellular localization of ß-catenin was investigated in 69 HCCs and adjacent cirrhotic and normal liver tissue. Normal liver showed diffuse membranous staining of ß-catenin in hepatocytes and an even stronger membranous staining in bile duct epithelium (Fig. 4A) . In contrast, cytoplasmic and nuclear accumulation of ß-catenin was found in 42 (60.9%) and 33 (47.8%) of 69 HCCs, Table III . p-Akt expression in human hepatocellular carcinomas and correlation with clinicopathological parameters.
- 
p-Akt expression was scored as described in Materials and methods. Kruskal-Wallis or Mann-Whitney test. A p-value <0.05 was considered statistically significant. Table IV . ß-catenin expression in human hepatocellular carcinomas and correlation with clinicopathological parameters. 
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a ß-catenin expression was scored as described in Materials and methods. Kruskal-Wallis or Mann-Whitney test. A p-value <0.05 was considered statistically significant.
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respectively (Fig. 4B) . Loss of membranous ß-catenin expression was observed in 53/69 (76.8%) HCCs and only 16/69 (23.1%) tumors showed a focal weak or moderate membranous staining. There was no significant correlation of nuclear, cytoplasmic or membranous ß-catenin expression with tumor grade (Table IV) . However, membranous ß-catenin expression was significantly higher in tumors without coexistent cirrhosis, compared to tumors with underlying cirrhotic liver parenchyma (p=0.002). There was also a strong positive correlation between nuclear and cytoplasmic ß-catenin expression (p<0.001). In cirrhotic liver, focal membranous expression of ß-catenin in hepatocytes was observed in only 10/47 (21.3%) cases, while strong membranous expression in proliferative bile ductule epithelium was retained in all cases. No cytoplasmic or nuclear staining of ß-catenin in cirrhosis was noted (Fig. 4C) . It is important to note that ILK expression did not correlate with nuclear, cytoplasmic or membranous ß-catenin expression.
Downregulation of E-cadherin in HCC and liver cirrhosis does not correlate with ILK expression.
The expression of E-cadherin was examined in 69 HCCs and adjacent cirrhotic and normal liver tissue. In normal liver there was a strong membranous staining of E-cadherin in hepatocytes and bile ductule epithelial cells (Fig. 4D) . In contrast HCCs showed complete loss or weak focal expression of E-cadherin in 59/69 (85.5%) cases (Fig. 4E) and negative or weak membranous expression of E-cadherin was also observed in 30/47 (63.9%) cases of cirrhosis (Fig. 4F) . However, there was no statistically significant difference in the expression levels of E-cadherin between cirrhosis and HCCs. The expression of E-cadherin in HCCs did not correlate with tumor grade but was statistically significantly lower in tumors without underlying cirrhosis (p=0.007) ( Table V) . We did not find any correlation between E-cadherin and ILK expression in HCC or cirrhosis.
Discussion
ILK has been shown to regulate signaling pathways that are crucial for cell survival, proliferation, cell adhesion, migration and carcinogenesis (19) . In the present study, we examined the ILK protein expression profile in human hepatocellular carcinomas and liver cirrhosis by immunohistochemistry. We also evaluated the correlation between ILK, p-Akt, E-cadherin and ß-catenin and their relation to clinicopathological parameters. ILK cytoplasmic overexpression was observed in all tumor specimens in contrast to normal liver where ILK expression was absent or very weak. Consistently, overexpression of ILK has been shown in various human tumors such as melanoma, prostate and colon cancer (11, 12, 14) . In vitro data also implicate ILK in multiple aspects of malignant development and progression, including anchorage-independent cell growth and survival, migration and invasion (5, 6) . Moreover, ILK has been shown to be involved in chemically-induced hepatocarcinogenesis and while preparing our manuscript Intaraprasong et al reported overexpression of ILK in human HCC (18) . Taken together, these data suggest that ILK overexpression is implicated in liver oncogenesis.
There was no correlation of ILK expression with tumor differentiation of HCC. This finding is in agreement with previous reports in gastric and lung cancer where ILK expression did not correlate with tumor grade (20, 21) . In contrast, other studies in ovarian tumors, prostate and colon cancer found that the intensity of ILK-specific immunostaining was positively correlated with advancing tumor grade (11) (12) (13) . Our data support the notion that ILK expression in HCC may not be involved in tumor grade progression.
Importantly, elevated levels of ILK were also found in cirrhotic liver tissue compared to normal liver suggesting a role of ILK in liver cirrhosis. It is known that activation of hepatic stellate cells (HSCs) plays a key role in the development of liver cirrhosis (22) . Consistent with our finding of ILK overexpression in human cirrhotic liver specimens, ILK was previously found to be overexpressed in liver from rats with chemical-induced cirrhosis, while culture activation of HSCs was accompanied by a marked upregulation of ILK (23). In the same study, ILK was shown to be critically involved in the regulation of HSC migration, proliferation and apoptosis (23) . ILK overexpression has also been observed in renal fibrosis and TGF-ß, a critical inducer of liver fibrosis, has been shown to regulate ILK levels in kidney interstitial cells (24) .
Most of the HCCs examined demonstrated activation of Akt. It is well established that the serine/threonine protein kinase Akt plays a key role in carcinogenesis by stimulating cell proliferation and inhibiting apoptosis (25) . Consistent with our findings, phosphorylation of Akt that leads to its activation has been observed in a variety of tumors including hepatocellular carcinoma (26) . A recent study also demonstrated the critical involvement of Akt phosphorylation in the aggressiveness of HCC and identified p-Akt as a significant prognostic factor (27) . However, in our study, there was no correlation of Akt with advancing tumor grade. Notably, phosphorylation of Akt in HCC was higher in tumors in which non-tumoral liver showed no fibrosis, regeneration or other evidence of cirrhosis. Etiological factors of HCC in non-cirrhotic liver are often unidentified, and distinct molecular mechanisms of oncogenesis are probably involved (28) . It seems likely that activation of Akt may be related to molecular events that lead to hepatocarcinogenesis in the absence of cirrhosis.
One important finding of our study was the significant correlation of p-Akt with ILK overexpression in human HCC. ILK is known to play a role as an upstream regulator of Akt by stimulating the phosphorylation of Akt on serine residue 473 (10). This interaction has been supported mainly by in vitro (9, 29, 30 ) and a few in vivo studies (12, 21) . Our results suggest that ILK is probably involved in the activation of Akt during human hepatocarcinogenesis.
Increased phosphorylation of Akt was also observed in liver cirrhosis indicating its potential role in this process. In agreement with our finding, previous in vitro studies have reported that activation of the Akt pathway is involved in liver fibrosis by inducing the proliferation, migration and survival Table V . E-cadherin expression in human hepatocellular carcinomas and correlation with clinicopathological parameters. 
of HSCs (31, 32) . The PI3K-Akt pathway has been shown to mediate platelet-derived growth factor (PDGF)-induced HSC proliferation (32) . Activated Akt has also been demonstrated to result in downregulation of p27kip1 leading HSCs into the S/G2/M phase of the cell cycle and proliferation (31) . Additionally, we found a significant correlation of p-Akt with ILK expression in cirrhotic liver tissue suggesting a functional correlation of ILK and Akt signaling in the development of cirrhosis. In line with this hypothesis, in vitro studies have shown that ILK is critically involved in the phosphorylation of Akt in activated HSCs (23) .
In addition to its role in HSC activation, ILK signaling is involved in inflammatory processes. Specifically, ILK has been shown to regulate inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-κB-dependent manner and to be implicated in leukocyte trafficking and survival (33, 34) . Many of these ILK functions are mediated via activation of Akt (33, 34) . Chronic inflammation significantly accounts for the generation of mutagenic and mitotic stimuli that lead from cirrhosis to HCC (35) . Therefore, the implication of ILK signaling in inflammatory responses and liver wound healing suggests that overexpression of ILK and subsequent activation of Akt may represent a molecular link between cirrhosis and HCC.
Activation of ß-catenin and downregulation of E-cadherin were frequently observed in our cases of HCC in accordance with several previous studies (36) (37) (38) (39) . ILK did not correlate with ß-catenin or E-cadherin in HCC although several studies in epithelial cell lines support an important role of ILK in ß-catenin activation and in the regulation of E-cadherin expression (7, 40) . It seems likely that in liver oncogenesis mechanisms other than overexpression of ILK account for the observed deregulation of ß-catenin and E-cadherin. In line with this hypothesis, it has been shown that mutations of the Wnt signaling pathway components may be prerequisites for the nuclear accumulation of ß-catenin in hepatocellular carcinomas (37, 41) . Moreover, loss of E-cadherin in HCC is frequently attributed to genetic or epigenetic alteration of the E-cadherin gene (42) .
Reduced membranous ß-catenin and E-cadherin expression was also observed in cirrhotic tissue. However, cytoplasmic/ nuclear staining of ß-catenin was not found in cirrhosis consistent with previous reports (36, 37) . In agreement with our findings, loss of E-cadherin in cirrhotic liver tissue due to promoter methylation has been previously reported (43) . These data suggest that loss of cell to cell adhesion as a result of E-cadherin downregulation or decreased membranous ß-catenin may contribute to the abnormal structural reorganization observed in liver cirrhosis.
In conclusion, ILK overexpression and activation of Akt are frequent events in human hepatocellular carcinoma and liver cirrhosis suggesting their involvement in the pathogenesis of these processes. HCC also showed activation of ß-catenin and downregulation of E-cadherin while loss of membranous E-cadherin and ß-catenin was a prominent feature in cirrhosis. While there was no correlation of ILK and ß-catenin or E-cadherin, ILK correlated significantly with activation of Akt in both HCC and cirrhotic liver suggesting an in vivo functional association of ILK and Akt during liver oncogenesis and cirrhosis.
